Compare PNNT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | VSTM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.7M | 470.7M |
| IPO Year | 2007 | 2011 |
| Metric | PNNT | VSTM |
|---|---|---|
| Price | $4.90 | $5.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $5.85 | ★ $15.00 |
| AVG Volume (30 Days) | 751.9K | ★ 1.5M |
| Earning Date | 02-09-2026 | 03-04-2026 |
| Dividend Yield | ★ 19.67% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $254.18 |
| Revenue Next Year | N/A | $99.39 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $4.56 | $4.01 |
| 52 Week High | $7.53 | $11.25 |
| Indicator | PNNT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 39.93 |
| Support Level | $4.84 | $5.56 |
| Resistance Level | $6.18 | $6.66 |
| Average True Range (ATR) | 0.15 | 0.36 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 52.50 | 10.45 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.